In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Read the full coverage here: Blue-collar workers more likely to miss work, quit due to psoriatic arthritis Infliximab biosimilar uptake rapidly increased only after release of a third option National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala Safety checklist compiles clinically important DMARD warnings in one place Guselkumab demonstrates long-term efficacy, safety in psoriasis References: Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1. Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1. Press Release Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963. Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.

Ver todos los episodios